Dr Reddy’s Opens New 70,000 sq ft Biologics Facility in Hyderabad

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00


Dr Reddy’s Laboratories inaugurated a 70,000 sq ft biologics facility in Genome Valley, Hyderabad, through its subsidiary Aurigene, emphasising process and analytical development for antibodies and recombinant proteins. It aligns with Dr Reddy’s commitment to advancing biologics research and development.

Dr Reddy’s Labs News Today

Dr Reddy’s Laboratories revealed the inauguration of a new biologics facility spanning 70,000 sq ft in Genome Valley, Hyderabad, operated by its subsidiary, Aurigene Pharmaceutical Services Limited. The facility aims to address process and analytical development and small-scale manufacturing requirements for antibodies and other recombinant proteins.

Explore: Dr. Reddy's Laboratories

Enhancing Capabilities

While the process and analytical development laboratories are already operational, the manufacturing capacity is slated for completion later in 2024, as per a regulatory filing by Dr Reddy’s Labs.

This addition complements the company’s existing infrastructure, concentrating on various recombinant proteins such as monoclonal antibodies (mAbs), bi- and multi-specifics, and immune-fusion molecules.

Comprehensive Service Offering

Aurigene's service spectrum now covers discovery to large-scale commercial manufacturing, facilitated by three nearby campuses. This alignment ensures seamless progression from conceptualization to commercialization, catering to diverse customer needs.

Strategic Growth Initiatives

Aurigene CEO Akhil Ravi expressed confidence that the new facility's capabilities will enhance global customer service and support innovative medicine development.

Dr Roger Lias, Aurigene's global commercial head for biologics, emphasised the rarity of global CDMOs providing end-to-end services, highlighting Aurigene's strengthened capabilities and technical prowess.

Industry Developments

The industry also witnessed Aurobindo Pharma's subsidiary, TheraNym Biologics Pvt Ltd, securing a contract manufacturing agreement with Merck Sharpe & Dohme Singapore Trading Pte Ltd for biological production. Additionally, researchers at IISc introduced a safer protein production method using MSG, replacing hazardous methanol.

This comprehensive expansion underscores Dr Reddy’s commitment to strengthening its biologics capabilities and serving the evolving needs of the pharmaceutical industry.

Additional Read: Dr. Reddy's Laboratories Ltd.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7.5 Lacs+ Users


4.3+ App Rating


4 Languages


₹4300 Cr MTF Book